Donanemab slows clinical decline of Alzheimer's disease in phase II TRAILBLAZER-ALZ study

Study (n=272) found that this investigational antibody that targets a modified form of beta amyloid called N3pG, slowed decline (RRR 32%) in a composite measure of cognition and daily function (iADRS) compared to placebo in patients with early symptomatic disease.

Biospace Inc.